WJCD  Vol.2 No.1 , January 2012
The effects of EPA + DHA and aspirin on inflammatory cytokines and angiogenesis factors
Objective: In a recent study, we showed that the combination of aspirin plus the ω3 fatty acids eicosapen-taenoic acid (EPA) and docosahexaenoic acid (DHA) synergistically inhibited platelet function. As aspirin, EPA, and DHA have demonstrated anti-inflammatory properties, we hypothesized that the ingestion of EPA and DHA, with and without aspirin, would reduce plasma levels of inflammatory cytokines and angiogenesis factors more than aspirin alone and before aspirin was ingested. Methods: Using multiplex technology, we investigated the effects of aspirin (single-dose 650 mg on day 1), EPA + DHA (3.4 g/d for days 2 - 29), and aspirin with EPA + DHA (day 30) on plasma levels of inflammatory cytokines and angiogenesis factors in healthy adults. Results: Aspirin alone had no effect on any factor versus baseline, but EPA + DHA, with and without aspirin, significantly reduced concentrations of 8 of 9 factors. Although EPA + DHA plus aspirin reduced concentrations of a subset of the factors compared to baseline, neither aspirin alone nor the combination significantly reduced the level of any analyte more robustly than EPA + DHA alone. Conclusions: These data suggest that EPA + DHA has more pronounced down-regulatory effects on inflammation and angiogenesis than aspirin. The implications of these findings for the use of combined therapy for cardiovascular disease remain to be clarified.

Cite this paper
Block, R. , Dier, U. , Artero, P. , Shearer, G. , Kakinami, L. , Larson, M. , Harris, W. , Georas, S. and Mousa, S. (2012) The effects of EPA + DHA and aspirin on inflammatory cytokines and angiogenesis factors. World Journal of Cardiovascular Diseases, 2, 14-19. doi: 10.4236/wjcd.2012.21003.
[1]   Bonow, R.O., Smaha, L.A., Smith, S.C., Jr, Mensah, G.A. and Lenfant, C. (2002) World Heart Day 2002: The international burden of cardiovascular disease: Responding to the emerging global epidemic. Circulation, 106, 1602- 1605. doi:10.1161/01.CIR.0000035036.22612.2B

[2]   Celletti, F.L., Waugh, J.M., Amabile, P.G., Brendolan, A., Hilfiker, P.R. and Dake, M.D. (2001) Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nature Medicine, 7, 425-429. doi:10.1038/86490

[3]   Serhan, C.N., Chiang, N. and Van, Dyke, T.E. (2008) Re- solving inflammation: Dual an-ti-inflammatory and pro- resolution lipid mediators. Nature Re-views Immunology, 8, 349-361. doi:10.1038/nri2294

[4]   Kereiakes, D.J. (2003) Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-ele- vation acute coronary syndromes: The role of modulating inflammation. Circulation, 108, III22-27. doi:10.1161/01.CIR.0000086951.09881.51

[5]   Kris-Etherton, P.M., Harris, W.S. and Appel, L.J. (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Cir-culation, 106, 2747-2757. doi:10.1161/01.CIR.0000086951.09881.51

[6]   Larson, M.K., Ashmore, J.H., Harris, K.A., Vogelaar, J.L., Pottala, J.V., Sprehe, M., et al. (2008) Effects of omega-3 acid ethyl esters and aspirin, alone and in com- bination, on platelet function in healthy subjects. Thromb Haemost, 100, 634-641.

[7]   Coleman, J.L. and Alberts, M.J. (2006) Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers. American Journal of Cardiology, 98, 838-841. doi:10.1016/j.amjcard.2006.03.071

[8]   Spencer, L., Mann, C., Metcalfe, M., Webb, M., Pollard, C., Spencer, D., et al. (2009) The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. European Journal of Cancer, 45, 2077-2086. doi:10.1016/j.ejca.2009.04.026

[9]   Wallace, J.M., McCabe, A.J., Roche, H.M., Higgins, S., Robson, P.J., Gilmore, W.S., et al. (2000) The effect of low-dose fish oil supplementation on serum growth factors in healthy humans. European Journal of Clinical Nutrition, 54, 690-694. doi:10.1038/sj.ejcn.1601076

[10]   Baumann, K.H., Hessel, F., Larass, I., Muller, T., Angerer, P., Kiefl, R., et al. (1999) Die-tary omega-3, omega-6, and omega-9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study. Ar-terioscler Thrombosis Vascular Biology, 19, 59-66. doi:10.1161/01.ATV.19.1.59

[11]   Calder, P.C. (2006) N-3 polyunsaturated fatty acids, in- flammation, and inflammatory diseases. American Journal of Clinical Nutrition, 83, 1505S-1519S.

[12]   Novak, T.E., Babcock, T.A., Jho, D.H., Helton, W.S. and Espat, N.J. (2003) NF-kappa B inhibition by omega -3 fatty acids modulates LPS-stimulated macrophage TNF- alpha transcription. American Journal of Physiology Lung Cellular and Molecular Physiology, 284, L84-L89.

[13]   Yin, R., Huang, H., Zhang, J., Zhu, J., Jing, H. and Li, Z. (2008) Dietary n-3 fatty acids attenuate cardiac allograft vasculopathy via activating peroxisome proliferator-acti- vated receptor-gamma. Pediatric Transplantation, 12, 550- 556. doi:10.1111/j.1399-3046.2007.00849.x

[14]   Kew, S., Mesa, M.D., Tricon, S., Buckley, R., Minihane, A.M. and Yaqoob P. (2004) Effects of oils rich in eicosapentaenoic and docosahex-aenoic acids on immune cell composition and function in healthy humans. American Journal of Clinical Nutrition, 79, 674- 681.

[15]   Khurana, R., Simons, M., Martin, J.F. and Zachary, I.C. (2005) Role of angiogenesis in cardiovascular disease: A critical appraisal. Circulation, 112, 1813-1824. doi:10.1161/CIRCULATIONAHA.105.535294

[16]   Simons, M. and Ware, J.A. (2003) Therapeutic angioge- nesis in cardi-ovascular disease. Nature Reviews Drug Dis- covery, 2, 863-871. doi:10.1038/nrd1226

[17]   Connor, K.M., SanGiovanni, J.P., Lofqvist, C., Aderman, C.M., Chen, J., Higuchi, A., et al. (2007) Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nature Medecine, 13, 868-873. doi:10.1038/nm1591

[18]   Ferrucci, L., Cherubini, A., Bandinelli, S., Bartali, B., Corsi, A., Lauretani, F., et al. (2006) Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. Journal of Clinical Endocrinology & Metablism, 91, 439-446. doi:10.1210/jc.2005-1303

[19]   Patrono, C., Garcia Rodriguez, L.A., Landolfi, R. and Baigent, C. (2005) Low-dose aspirin for the prevention of atherothrombosis. New England Journal of Medecine, 353, 2373-2383. doi:10.1056/NEJMra052717

[20]   Dasgupta, P. and Chellappan, S.P. (2006) Nicotine-me- diated cell proliferation and angioge-nesis: New twists to an old story. Cell Cycle, 5, 2324-2328. doi:10.4161/cc.5.20.3366

[21]   Losordo, D.W. and Dimmeler, S. (2004) Therapeutic an- giogenesis and vasculogenesis for ischemic disease: Part II: Cell-based therapies. Circulation, 109, 2692-2697. doi:10.1161/01.CIR.0000128596.49339.05